NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRXP NRX Pharmaceuticals Inc.

Market Closed 09-18 16:00:00 EDT

3.32

-0.07

-2.06%

盘后3.39

+0.07+2.11%

19:49 EDT

High3.42	Low3.31	Vol947.27K
Open3.38	D1 Closing3.39	Amplitude3.24%
Mkt Cap143.74M	Tradable Cap124.24M	Total Shares43.30M
T/O3.16M	T/O Rate2.53%	Tradable Shares37.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRXP","market":"US","secType":"STK","nameCN":"NRX Pharmaceuticals Inc.","latestPrice":3.32,"timestamp":1789761600000,"preClose":3.39,"halted":0,"volume":947272,"hourTrading":{"tag":"盘后","latestPrice":3.39,"preClose":3.32,"latestTime":"19:49 EDT","volume":70974,"amount":236227.7532,"timestamp":1789775362217,"change":0.07,"changeRate":0.021084,"amplitude":0.021084},"delay":0,"changeRate":-0.020648967551622502,"floatShares":37421400,"shares":43295800,"eps":-0.775423,"marketStatus":"Market Closed","change":-0.07,"latestTime":"09-18 16:00:00 EDT","open":3.38,"high":3.42,"low":3.31,"amount":3163637.7371016,"amplitude":0.032448,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.775423,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":3.39,"preHourTrading":{"tag":"盘前","latestPrice":3.4,"preClose":3.39,"latestTime":"09:29 EDT","volume":15329,"amount":52140.8469777,"timestamp":1789738141106,"change":0.01,"changeRate":0.00295,"amplitude":0.020649},"postHourTrading":{"tag":"盘后","latestPrice":3.39,"preClose":3.32,"latestTime":"19:49 EDT","volume":70974,"amount":236227.7532,"timestamp":1789775362217,"change":0.07,"changeRate":0.021084,"amplitude":0.021084},"volumeRatio":1.095248126926259,"impliedVol":2.0478,"impliedVolPercentile":0.7052},"requestUrl":"/m/hq/s/NRXP","defaultTab":"news","newsList":[{"id":"2667604726","title":"NRx Pharma Says FDA Reclassifies Ketamine ANDA Amendment as Minor, Sets Nov. 10, 2026 Goal Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2667604726","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667604726?lang=en_us&edition=fundamental","pubTime":"2026-09-16 18:04","pubTimestamp":1789553080,"startTime":"0","endTime":"0","summary":"NRx Pharma says FDA reclassifies ketamine ANDA amendment as minor, sets Nov. 10, 2026 goal dateNRX Pharmaceuticals received FDA notice reclassifying its ketamine ANDA amendment from major to minor, ea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL16nC4D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667621742","title":"NRx Pharmaceuticals says FDA reclassifies ANDA amendment to ‘minor’","url":"https://stock-news.laohu8.com/highlight/detail?id=2667621742","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667621742?lang=en_us&edition=fundamental","pubTime":"2026-09-16 03:15","pubTimestamp":1789499711,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals (NRXP) announced that it has received a written communication from the Director of Regulatory Operations of the FDA Office of G...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nrx-pharmaceuticals-says-fda-reclassifies-anda-amendment-to-minor-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nrx-pharmaceuticals-says-fda-reclassifies-anda-amendment-to-minor-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","PSIL","LABU","BK4007","NRXP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667621265","title":"NRX Pharmaceuticals - FDA Revises Gdufa Goal Date for Anda Amendment to November 10, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2667621265","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667621265?lang=en_us&edition=fundamental","pubTime":"2026-09-16 03:11","pubTimestamp":1789499515,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nFWN4570DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667624858","title":"NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine","url":"https://stock-news.laohu8.com/highlight/detail?id=2667624858","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667624858?lang=en_us&edition=fundamental","pubTime":"2026-09-16 03:11","pubTimestamp":1789499460,"startTime":"0","endTime":"0","summary":"Abbreviated New Drug Application (ANDA) Amendment related to the drug vial for preservative-free ketamine has been reclassified from a Major Amendment to a Minor Amendment.FDA has revised the Generic ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/15/3362609/0/en/nrx-pharmaceuticals-nasdaq-nrxp-reports-update-from-the-fda-revising-previous-major-amendment-to-a-minor-amendment-for-preservative-free-ketamine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","BK4007","BK4588","LABU","BK4585","NRXP","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667698261","title":"NRX Pharmaceuticals Price Target Maintained with a $10.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2667698261","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667698261?lang=en_us&edition=fundamental","pubTime":"2026-09-15 02:51","pubTimestamp":1789411860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668873","title":"NRx Pharma Unit GeNeuro Wins European Patent for ALS Antibody Candidate GNK-301","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668873","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668873?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:04","pubTimestamp":1789383892,"startTime":"0","endTime":"0","summary":"NRx Pharma unit GeNeuro wins European patent for ALS antibody candidate GNK-301NRx Pharmaceuticals’ GeNeuro unit won a European patent covering GNK-301, a monoclonal antibody targeting HERV-K envelope","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL34d93C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4585","BK4588","BK4007","NDAQ","LU0314104364.USD","IE00B64PRP62.GBP","IE00BQXX3F31.USD","GNK","BCDF","IE00BKPKM429.USD","NRXP","LU2210150020.SGD","LU2210149790.SGD","SG9999014039.USD","LU2095319765.USD","BK4112","IE00BGHQF748.EUR","SG9999014021.USD","IE00BQXX3D17.EUR","IE00BN0W2W23.USD","BK4021"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666892521","title":"NRX Pharmaceuticals' HOPE Therapeutics to Deploy Zeta's TMS Robotic System","url":"https://stock-news.laohu8.com/highlight/detail?id=2666892521","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666892521?lang=en_us&edition=fundamental","pubTime":"2026-09-11 19:32","pubTimestamp":1789126372,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals'  HOPE Therapeutics unit will deploy Zeta Surgical's TMS Robotic System in Florida, with its clinical staff already undergoing orientation and training, NRx said Friday.TMS is a non-invasive therapy mainly used for treatment-resistant depression, and the robotic system's deployment will support NRx's phase 2/3 trial of an NRX-101 combination therapy, the company said.Financial details of the deployment were not disclosed.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NRXP","BK4007","BK4139","PSIL","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322488","title":"NRx Pharma to Present at Moody Capital Solutions Disruptive Growth & Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322488","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322488?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:06","pubTimestamp":1788865578,"startTime":"0","endTime":"0","summary":"NRx Pharma to present at Moody Capital Solutions Disruptive Growth & Life Sciences ConferenceNRx Pharmaceuticals management will present at investor conferences in New York on Sept. 9, Sept. 11, Sept.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL1TRKCH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014039.USD","PSIL","SG9999014013.SGD","BK4007","IE00BQXX3D17.EUR","BK4585","IE00B3QW5Z07.USD","CFSU","SG9999014005.SGD","IE00BQXX3C00.GBP","NDAQ","SG9999014021.USD","IE00BN0W2W23.USD","NRXP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU0314104364.USD","BCDF","BK4112","IE00B64PRP62.GBP","LU2095319765.USD","IE00BQXX3F31.USD","BK4588","IE00BN0W2T93.GBP","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662560967","title":"NRX Pharmaceuticals Price Target Maintained with a $45.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662560967","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662560967?lang=en_us&edition=fundamental","pubTime":"2026-08-26 00:58","pubTimestamp":1787677080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469854","title":"NRX Pharmaceuticals Price Target Maintained with a $10.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469854","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660469854?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:09","pubTimestamp":1787047740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660292438","title":"NRX Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2660292438","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660292438?lang=en_us&edition=fundamental","pubTime":"2026-08-17 21:33","pubTimestamp":1786973588,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings SummaryNRX Pharmaceuticals IncNRXP.OQreported a quarterly adjusted loss of 44 cents per share for the quarter ended Jun","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL8N44E0V4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660904484","title":"NRX Pharmaceuticals Q2 EPS $(0.44) Misses $0.06 Estimate, Sales $1.101M Miss $17.488M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2660904484","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660904484?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:07","pubTimestamp":1786964859,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $0.06 by 833.33 percent. This is a 55.1 percent increase over losses of $(0.98) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61241856/nrx-pharmaceuticals-q2-eps-0-44-misses-0-06-estimate-sales-1-101m-miss-17-488m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660843574","title":"NRX Pharmaceuticals (Nasdaq:Nrxp) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17TH at 4:30Pm Et","url":"https://stock-news.laohu8.com/highlight/detail?id=2660843574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660843574?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:00","pubTimestamp":1786964401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA5NRC6D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660649484","title":"NRX Pharmaceuticals - Reports Cash and Cash Equivalents of $26.70 Mln as of June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660649484","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660649484?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:00","pubTimestamp":1786964401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA5NRC6D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484873","title":"Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484873","media":"Dow Jones","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660484873?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:00","pubTimestamp":1786964400,"startTime":"0","endTime":"0","summary":"Key recent and second quarter highlights include:-- Completed first-cycle FDA review of the Company's ANDA for. preservative-free ketamine with no drug-related major deficiencies. The. sole remaining item, a manufacturer's attestation on the vial, has been. -- Initiation of commercial scale manufacturing of preservative-free. ketamine building to launch stock of 5 million doses to be ready for. -- Selected by the Defense Advanced Research Projects Agency  as. prime contractor for SPARC-TMS, an FDA-approved Phase 2/3 trial of. NRX-101 with robotic TMS. Anticipated non-dilutive funding exceeds $11.5. -- The Company is advancing its NRX-100 NDA on Real World Evidence from more. than 65,000 patients, leveraging a Presidential Executive Order and. Congressional budget language that encourage FDA use of such evidence in. -- Closed an institutionally-supported, underwritten public offering of. common stock for gross proceeds of $22.3 million, including full exercise. of the underwriters' opti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PSIL","AMLP","EIPX","R","EMLP","EIPI","NQmain","BK4144","BK4588","BK4581","MLPA","UMI","TPZ","BK4022","ET","LABU","BK4561","BK4232","BK4590","MDST","ENFR","TNGY","USAI","AMZA","NRXP","BK4585","LCLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659121802","title":"NRx Pharma Q2 FY26 Net Loss Narrows to $16.52 Million; Revenue Rises to $1.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659121802","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659121802?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:41","pubTimestamp":1786740087,"startTime":"0","endTime":"0","summary":"NRx Pharma Q2 FY26 net loss narrows to $16.52 million; revenue rises to $1.1 millionNRX Pharmaceuticals posted a GAAP net loss of USD 16.52 million for the quarter ended June 30, 2026, narrowing from ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL9JWFzG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659141744","title":"NRX Pharmaceuticals Inc Expected to Post Earnings of 6 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2659141744","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659141744?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:59","pubTimestamp":1786712347,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc <NRXP.OQ> expected to post earnings of6cents a share - Earnings PreviewNRX Pharmaceuticals IncNRXP.OQNRXP.Ois expected to  show a rise in quarterly revenue when it reports  res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B0UP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626537","title":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626537","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626537?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:01","pubTimestamp":1786132860,"startTime":"0","endTime":"0","summary":"Conference Call 8:30 a.m. ET, Monday, August 10, 2026MIAMI, Aug.  07, 2026  (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\", the \"Company\"), a clinical-stage biopha","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/07/3341373/0/en/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSQ","QYLG","SQQQ","QID","ONEQ","PSIL","NDX","QQQY","NQmain","QQQA","TQQY","MNQmain","LABU","QQQE","BK4007","BK4585","TQQQ","QQQM","TECS","JEPQ","QQQJ","QDTE","BK4181","IYW","QLD","HST","QQQ","NRXP","FTEC","NVIW.SI","BK4218","BK4588",".IXIC","GPIQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657640437","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657640437","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657640437?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:30","pubTimestamp":1786120219,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-nrx-pharmaceuticals-nrxp-novo-nordisk-nvo-and-pfizer-pfe-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-nrx-pharmaceuticals-nrxp-novo-nordisk-nvo-and-pfizer-pfe-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SG9999001176.SGD","BK4532","LU0306806265.USD","BK4007","IE000M9KFDE8.USD","NRXP","OZEM","SG9999001176.USD","SG9999013999.USD","SG9999002232.USD","SG9999003800.SGD","BK4599","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","BK4533","IE0002270589.USD","BK4534","LU1883839398.USD","LU0122379950.USD","LU1093756325.SGD","LU0321505868.SGD","LU0058720904.USD","LU1093756168.USD","PSIL","BK4585","LU0321505439.SGD","NVO","BK4550","LU1894683348.USD","IE00BBT3K403.USD","SG9999002224.SGD","LU1066051498.USD","IE00B3T34201.USD","SG9999011175.SGD","LU0225771236.USD","IE00BKVL7J92.USD","LU0154236417.USD","LU0306807586.USD","BK4568","BK4581","LU0289739699.SGD","BK4592","LU0170899867.USD","LU1894683264.USD","BK4588","LU1066053197.SGD","THNR","LU0985481810.HKD","LU0456855351.SGD","PFE","LU0225284248.USD","LU0234572021.USD","NVOH","LU1057294990.SGD","PPH","IE00B19Z3581.USD","IE00BLSP4452.SGD","LU0868494617.USD","SGXZ57979304.SGD","LU2596442595.SGD","NVOX","LU1023059063.AUD","IE00BLSP4239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657980640","title":"NRx Pharmaceuticals Shares Rise After FDA Finishes Ketamine Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2657980640","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657980640?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:24","pubTimestamp":1786119840,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals shares rose after the Food and Drug Administration completed its abbreviated new drug application review of the company's ketamine product.The stock climbed 21% to $3.73 on Friday. Shares are up 42% this year.The first-cycle review evaluated NRx's preservative-free ketamine and found no major deficiencies related to the product, ingredients or labeling, the drug company said Friday.The FDA did flag a remaining question related to the container closure of the medication vial. The issue is packaging-related and doesn't relate to the ketamine drug product itself, NRx said.The company is providing an attestation to the FDA related to the packaging issue.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","PSIL","BK4007","NRXP","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.salbergco.com","stockEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":-0.003},{"period":"3month","weight":-0.1637},{"period":"6month","weight":0.7946},{"period":"1year","weight":0.1141},{"period":"ytd","weight":0.2251}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0096},{"period":"3month","weight":0.02},{"period":"6month","weight":0.1744},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.117}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.074525},{"month":2,"riseRate":0.2,"avgChangeRate":-0.102766},{"month":3,"riseRate":0.4,"avgChangeRate":-0.034339},{"month":4,"riseRate":0.4,"avgChangeRate":-0.100305},{"month":5,"riseRate":0.8,"avgChangeRate":0.153649},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.15132},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.005215},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.100965},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.018309},{"month":10,"riseRate":0.6,"avgChangeRate":0.037482},{"month":11,"riseRate":0.4,"avgChangeRate":0.048439},{"month":12,"riseRate":0.6,"avgChangeRate":0.121824}],"exchange":"NASDAQ","name":"NRX Pharmaceuticals Inc.","nameEN":"NRX Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NRX Pharmaceuticals Inc.,NRXP,NRX Pharmaceuticals Inc.股票,NRX Pharmaceuticals Inc.股票老虎,NRX Pharmaceuticals Inc.股票老虎国际,NRX Pharmaceuticals Inc.行情,NRX Pharmaceuticals Inc.股票行情,NRX Pharmaceuticals Inc.股价,NRX Pharmaceuticals Inc.股市,NRX Pharmaceuticals Inc.股票价格,NRX Pharmaceuticals Inc.股票交易,NRX Pharmaceuticals Inc.股票购买,NRX Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction